183 related articles for article (PubMed ID: 31238096)
1. Exploiting metabolic vulnerabilities of Non small cell lung carcinoma.
Majem B; Nadal E; Muñoz-Pinedo C
Semin Cell Dev Biol; 2020 Feb; 98():54-62. PubMed ID: 31238096
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies for advanced non-small cell lung cancer.
Starakis I; Nikolakopoulos A; Mazokopakis EE
Comb Chem High Throughput Screen; 2012 Sep; 15(8):641-55. PubMed ID: 22409867
[TBL] [Abstract][Full Text] [Related]
4. Roles of exosomes in the carcinogenesis and clinical therapy of non-small cell lung cancer.
Liu S; Zhan Y; Luo J; Feng J; Lu J; Zheng H; Wen Q; Fan S
Biomed Pharmacother; 2019 Mar; 111():338-346. PubMed ID: 30590322
[TBL] [Abstract][Full Text] [Related]
5. [Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
Wu S; Hu C; Wu F; Wu Y; Liu P
Zhongguo Fei Ai Za Zhi; 2019 Jul; 22(7):440-448. PubMed ID: 31315783
[TBL] [Abstract][Full Text] [Related]
6. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
7. Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.
Le Grand M; Berges R; Pasquier E; Montero MP; Borge L; Carrier A; Vasseur S; Bourgarel V; Buric D; André N; Braguer D; Carré M
Sci Rep; 2017 Mar; 7():45136. PubMed ID: 28332584
[TBL] [Abstract][Full Text] [Related]
8. Metabolic Heterogeneity in Human Lung Tumors.
Hensley CT; Faubert B; Yuan Q; Lev-Cohain N; Jin E; Kim J; Jiang L; Ko B; Skelton R; Loudat L; Wodzak M; Klimko C; McMillan E; Butt Y; Ni M; Oliver D; Torrealba J; Malloy CR; Kernstine K; Lenkinski RE; DeBerardinis RJ
Cell; 2016 Feb; 164(4):681-94. PubMed ID: 26853473
[TBL] [Abstract][Full Text] [Related]
9. Shining a light on metabolic vulnerabilities in non-small cell lung cancer.
Dowling CM; Zhang H; Chonghaile TN; Wong KK
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188462. PubMed ID: 33130228
[TBL] [Abstract][Full Text] [Related]
10. Suppression of reactive oxygen species-mediated ERK and JNK activation sensitizes dihydromyricetin-induced mitochondrial apoptosis in human non-small cell lung cancer.
Kao SJ; Lee WJ; Chang JH; Chow JM; Chung CL; Hung WY; Chien MH
Environ Toxicol; 2017 Apr; 32(4):1426-1438. PubMed ID: 27539140
[TBL] [Abstract][Full Text] [Related]
11. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
Langer CJ; Mok T; Postmus PE
Cancer Treat Rev; 2013 May; 39(3):252-60. PubMed ID: 22703830
[TBL] [Abstract][Full Text] [Related]
12. Integrating new targeted agents into the treatment of non-small-cell lung cancer.
Thatcher N
Lung Cancer; 2006 Dec; 54 Suppl 2():S25-31. PubMed ID: 17056150
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.
Nagano T; Tachihara M; Nishimura Y
Curr Cancer Drug Targets; 2019; 19(8):595-630. PubMed ID: 30526458
[TBL] [Abstract][Full Text] [Related]
14. Glucose metabolism provide distinct prosurvival benefits to non-small cell lung carcinomas.
Wu R; Galan-Acosta L; Norberg E
Biochem Biophys Res Commun; 2015 May; 460(3):572-7. PubMed ID: 25819414
[TBL] [Abstract][Full Text] [Related]
15. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
16. Current FDA-approved treatments for non-small cell lung cancer and potential biomarkers for its detection.
Ruiz-Ceja KA; Chirino YI
Biomed Pharmacother; 2017 Jun; 90():24-37. PubMed ID: 28340378
[TBL] [Abstract][Full Text] [Related]
17. Emerging new agents for the management of patients with non-small cell lung cancer.
Capelletto E; Novello S
Drugs; 2012 Jun; 72 Suppl 1():37-52. PubMed ID: 22712796
[TBL] [Abstract][Full Text] [Related]
18. Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
Chen C; Ju R; Shi J; Chen W; Sun F; Zhu L; Li J; Zhang D; Ye C; Guo L
J Pharmacol Exp Ther; 2017 Aug; 362(2):219-229. PubMed ID: 28515157
[TBL] [Abstract][Full Text] [Related]
19. Cordycepin Inhibits Drug-resistance Non-small Cell Lung Cancer Progression by Activating AMPK Signaling Pathway.
Wei C; Yao X; Jiang Z; Wang Y; Zhang D; Chen X; Fan X; Xie C; Cheng J; Fu J; Leung EL
Pharmacol Res; 2019 Jun; 144():79-89. PubMed ID: 30974169
[TBL] [Abstract][Full Text] [Related]
20. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
Chattopadhyay N; Berger AJ; Koenig E; Bannerman B; Garnsey J; Bernard H; Hales P; Maldonado Lopez A; Yang Y; Donelan J; Jordan K; Tirrell S; Stringer B; Xia C; Hather G; Galvin K; Manfredi M; Rhodes N; Amidon B
PLoS One; 2015; 10(12):e0144825. PubMed ID: 26709701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
